Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne (MXMIN-001)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Darier.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Darier
ClinicalTrials.gov Identifier:
NCT00988026
First received: September 30, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

September 30, 2009
September 30, 2009
June 2009
February 2010   (final data collection date for primary outcome measure)
Number of inflammatory and non-inflammatory acne lesions [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
Incidence of local and systemic adverse events [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatment of Mild to Moderate Acne
Safety and Efficacy Comparison of Minocycline Microgranules vs Lymecycline in the Treatment of Mild to Moderate Acne. Randomized, Double Blind, Parallel and Prospective Clinical Trial for 8 Weeks

This is a clinical trial to compare the benefits and possible adverse events of two antibiotic treatments for mild to moderate acne. It is expected that minocycline microgranules will be more effective than lymecycline with a better adverse events profile.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Mild to Moderate Acne
Drug: Minocycline vs Lymecycline
Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
  • Experimental: Minocycline 100 mg
    Minocycline
    Intervention: Drug: Minocycline vs Lymecycline
  • Active Comparator: Lymecycline 300 mg
    Group B: Lymecycline
    Intervention: Drug: Minocycline vs Lymecycline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
168
April 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Both gender
  • 14 to 30 years old
  • Mild to moderate acne
  • Face localization
  • At least 20 non-inflammatory lesions OR
  • At least 15 inflammatory lesions OR
  • At least 30 total lesions AND
  • Less than 5 nodular lesions

Exclusion Criteria:

  • Patients younger than 14 or older than 30 years old
  • Less than 20 non-inflammatory lesions OR
  • Less than 15 inflammatory lesions OR
  • Less than 30 total lesions
  • Patients with severe acne
  • More than 5 nodular lesions OR
  • More than 50 inflammatory lesions OR
  • More than 125 total lesions
  • Pregnant women
  • Lactating women
Both
14 Years to 30 Years
No
Contact: Luis Leobardo Velázquez-Arenas, MD (5281)83481465 leovel2002@yahoo.com.mx
Contact: Jorge Ocampo-Candiani, MD (5281)83481465 jocampo2000@yahoo.com.mx
Mexico
 
NCT00988026
MXMIN-001
Yes
Luis Leobardo Velázquez-Arenas, Hospital "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo Léon
Darier
Not Provided
Not Provided
Darier
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP